Cargando…
A perspective on HPK1 as a novel immuno-oncology drug target
In this perspective review, the role Hematopoietic Progenitor Kinase 1 (HPK1) in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity cycle by this regulatory kinase. The review will highlight the strengths and weakn...
Autores principales: | Sawasdikosol, Sansana, Burakoff, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478889/ https://www.ncbi.nlm.nih.gov/pubmed/32896273 http://dx.doi.org/10.7554/eLife.55122 |
Ejemplares similares
-
Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response
por: Alzabin, Saba, et al.
Publicado: (2009) -
Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma
por: Sarkari, Akshat, et al.
Publicado: (2023) -
HPK1 tones down the T cell receptor
por: Leslie, Mitch
Publicado: (2011) -
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
por: You, Dan, et al.
Publicado: (2021) -
Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening
por: Ge, Huizhen, et al.
Publicado: (2022)